Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-Blind Placebo-Controlled Trial Of The Safety, Toleration and Efficacy Of Lasofoxifene 0.25 Mg/D and Raloxifene 60Mg/D For The Prevention Of Bone Loss In Postmenopausal Women

NCT00163137 is registered in ClinicalTrials.gov with Ligand Pharmaceuticals as lead sponsor.

NCT NCT00163137
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00163137 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-Blind Placebo-Controlled Trial Of The Safety, Toleration and Efficacy Of Lasofoxifene 0.25 Mg/D and Raloxifene 60Mg/D For The Prevention Of Bone Loss In Postmenopausal Women
Lead sponsor
Ligand Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2003
Completion date
October 31, 2005
Enrollment
540 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis